Summary & Overview
HCPCS Q9950: Sulfur Hexafluoride Lipid Microspheres Injection, per ml
HCPCS Level II code Q9950 denotes an injectable ultrasound contrast agent: sulfur hexafluoride lipid microspheres, billed per milliliter. Ultrasound contrast agents improve visualization in echocardiography and other ultrasound studies, supporting diagnostic accuracy and impacting imaging workflows and cost profiles nationwide. Use of this agent is clinically relevant for cardiology, radiology, and vascular imaging.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The analysis reviews how these payers approach coverage and billing for contrast-enhanced ultrasound agents and places Q9950 within broader imaging service lines.
Readers will find benchmarks for utilization and billing practices where available, a summary of payer coverage approaches, and clinical context on when sulfur hexafluoride lipid microsphere injections are used in diagnostic ultrasound. The report also summarizes common modifiers associated with imaging service lines and highlights gaps where data were not provided. Data not available in the input are noted as such. This summary is intended for national audiences seeking concise guidance on coding, clinical use, and payer considerations for HCPCS Level II code Q9950.
Billing Code Overview
HCPCS Level II code Q9950 describes Injection, sulfur hexafluoride lipid microspheres, per ml. This code represents a contrast agent administered by injection used to enhance ultrasound imaging, typically formulated as sulfur hexafluoride encapsulated in lipid microspheres.
Service type: Contrast agent injection for diagnostic ultrasound
Typical site of service: Imaging centers, hospital outpatient departments, and ambulatory surgical centers
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult presenting for contrast-enhanced echocardiography or ultrasound of abdominal or vascular structures where improved endocardial border definition or enhanced lesion conspicuity is required. A cardiology patient with technically limited transthoracic echocardiography due to obesity or chronic lung disease is referred for a contrast-enhanced transthoracic echo. The clinical workflow: the sonographer performs baseline ultrasound imaging, documents suboptimal visualization of cardiac chambers or target organ, notifies the supervising physician, obtains informed consent, and prepares the contrast agent Q9950 (sulfur hexafluoride lipid microspheres). The contrast is reconstituted per manufacturer instructions, drawn into syringes, and administered intravenously (typically via antecubital or peripheral IV) while real-time imaging is performed by the sonographer and interpreted by the cardiologist or radiologist. The interpreting physician documents baseline image limitations, indication for contrast, dose administered in milliliters, response of enhancement, and any immediate adverse reactions. Post-procedure monitoring is completed per institutional protocol before patient discharge or transfer.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing separately for the physician interpretation of the contrast-enhanced study. |